{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:19:02Z","timestamp":1779164342070,"version":"3.51.4"},"reference-count":34,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>Meningiomas are one of the most frequently occurring brain tumors and can be curatively treated with gross-total resection. A subtotal resection increases the chances of recurrence. The intraoperative identification of invisible tumor remnants by using a fluorescent tracer targeting an upregulated biomarker could help to optimize meningioma resection. This is called molecular fluorescence-guided surgery (MFGS). Vascular endothelial growth factor \u03b1 (VEGF\u03b1) has been identified as a suitable meningioma biomarker and can be targeted with bevacizumab-IRDye800CW.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>The aim of this prospective phase I trial was to determine the safety and feasibility of bevacizumab-IRDye800CW for MFGS for intracranial meningiomas by administering 4.5, 10, or 25 mg of the tracer 2\u20134 days prior to surgery. Fluorescence was verified during the operation with the standard neurosurgical microscope, and tissue specimens were postoperatively analyzed with fluorescence imaging systems (Pearl and Odyssey CLx) and spectroscopy to determine the optimal dose. Uptake was compared in several tissue types and correlated with VEGF\u03b1 expression.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>No adverse events related to the use of bevacizumab-IRDye800CW occurred. After two interim analyses, 10 mg was the optimal dose based on ex vivo tumor-to-background ratio. Although the standard intraoperative imaging revealed no fluorescence, postoperative analyses with tailored imaging systems showed high fluorescence uptake in tumor compared with unaffected dura mater and brain. Additionally, tumor invasion of the dura mater (dural tail) and invasion of bone could be distinguished using fluorescence imaging. Fluorescence intensity showed a good correlation with VEGF\u03b1 expression.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSIONS<\/jats:title>\n<jats:p>Bevacizumab-IRDye800CW can be safely used in patients with meningioma; 10 mg bevacizumab-IRDye800CW provided an adequate tumor-to-background ratio. Adjustments of the currently available neurosurgical microscopes are needed to achieve visualization of targeted IRDye800CW intraoperatively. A phase II\/III trial is needed to methodically investigate the benefit of MFGS with bevacizumab-IRDye800CW for meningioma surgery in a larger cohort of patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.3171\/2024.4.jns232766","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T03:09:12Z","timestamp":1720235352000},"page":"1655-1666","source":"Crossref","is-referenced-by-count":9,"title":["Bevacizumab-IRDye800CW for tumor detection in fluorescence-guided meningioma surgery (LUMINA trial): a single-center phase I study"],"prefix":"10.3171","volume":"141","author":[{"given":"Bianca M.","family":"Dijkstra","sequence":"first","affiliation":[{"name":"Departments of Neurosurgery,"},{"name":"Department of Neurosurgery, Maastricht UMC+, Maastricht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quirine C. F.","family":"Cordia","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Nonnekens","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert Jan","family":"Meersma","sequence":"additional","affiliation":[{"name":"Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata Sasank","family":"Donthu","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter B.","family":"Nagengast","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schelto","family":"Kruijff","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; and"},{"name":"Surgery, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred F. A.","family":"den Dunnen","sequence":"additional","affiliation":[{"name":"Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A. E.","family":"Kruyt","sequence":"additional","affiliation":[{"name":"Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J. M.","family":"Groen","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"},{"name":"Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"issue":"3","key":"b1","series-title":"Biomedicines","first-page":"319","article-title":"Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions","volume":"9","author":"Ogasawara C","year":"2021","unstructured":"Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021;9(3):319."},{"issue":"1","key":"b2","series-title":"J Neurol Neurosurg Psychiatry","first-page":"22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson D","year":"1957","unstructured":"Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22\u201339."},{"issue":"3","key":"b3","series-title":"Expert Rev Neurother","first-page":"241","article-title":"Current treatment options for meningioma","volume":"18","author":"Apra C","year":"2018","unstructured":"Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018;18(3):241\u2013249."},{"issue":"8","key":"b4","series-title":"Acta Neurochir (Wien)","first-page":"1539","article-title":"SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery","volume":"160","author":"Dijkstra BM","year":"2018","unstructured":"Dijkstra BM, Motekallemi A, den Dunnen WFA,  SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery. Acta Neurochir (Wien). 2018;160(8):1539\u20131546."},{"issue":"2","key":"b5","series-title":"Brain Tumor Pathol","first-page":"99","article-title":"Angiogenesis in meningiomas","volume":"28","author":"Barresi V","year":"2011","unstructured":"Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathol. 2011;28(2):99\u2013106."},{"issue":"10","key":"b6","series-title":"BMJ Open","first-page":"e049109","article-title":"Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial","volume":"11","author":"Vergeer RA","year":"2021","unstructured":"Vergeer RA, Postma MR, Schmidt I,  Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial. BMJ Open. 2021;11(10):e049109."},{"issue":"11","key":"b7","series-title":"Clin Cancer Res","first-page":"2730","article-title":"Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study","volume":"23","author":"Lamberts LE","year":"2017","unstructured":"Lamberts LE, Koch M, de Jong JS,  Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res. 2017;23(11):2730\u20132741."},{"issue":"1","key":"b8","series-title":"Nat Commun","first-page":"3739","article-title":"Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers","volume":"9","author":"Koller M","year":"2018","unstructured":"Koller M, Qiu SQ, Linssen MD,  Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers. Nat Commun. 2018;9(1):3739."},{"issue":"4","key":"b9","series-title":"Lancet Gastroenterol Hepatol","first-page":"283","article-title":"Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study","volume":"1","author":"Harlaar NJ","year":"2016","unstructured":"Harlaar NJ, Koller M, de Jongh SJ,  Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol Hepatol. 2016;1(4):283\u2013290."},{"issue":"5","key":"b10","series-title":"J Nucl Med","first-page":"655","article-title":"Back-table fluorescence-guided imaging for circumferential resection margin evaluation using bevacizumab-800CW in patients with locally advanced rectal cancer","volume":"61","author":"de Jongh SJ","year":"2020","unstructured":"de Jongh SJ, Tjalma JJJ, Koller M,  Back-table fluorescence-guided imaging for circumferential resection margin evaluation using bevacizumab-800CW in patients with locally advanced rectal cancer. J Nucl Med. 2020;61(5):655\u2013661."},{"issue":"6","key":"b11","series-title":"Theranostics","first-page":"1458","article-title":"Potential red-flag identification of colorectal adenomas with wide-field fluorescence molecular endoscopy","volume":"8","author":"Hartmans E","year":"2018","unstructured":"Hartmans E, Tjalma JJJ, Linssen MD,  Potential red-flag identification of colorectal adenomas with wide-field fluorescence molecular endoscopy. Theranostics. 2018;8(6):1458\u20131467."},{"issue":"3","key":"b12","series-title":"J Nucl Med","first-page":"342","article-title":"Fluorescence-guided visualization of soft-tissue sarcomas by targeting vascular endothelial growth factor A: a phase 1 single-center clinical trial","volume":"62","author":"Steinkamp PJ","year":"2021","unstructured":"Steinkamp PJ, Pranger BK, Li MF,  Fluorescence-guided visualization of soft-tissue sarcomas by targeting vascular endothelial growth factor A: a phase 1 single-center clinical trial. J Nucl Med. 2021;62(3):342\u2013347."},{"issue":"5","key":"b13","series-title":"J Neurosurg","first-page":"1263","article-title":"Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery","volume":"138","author":"Dijkstra BM","year":"2022","unstructured":"Dijkstra BM, Nonnekens J, Nagengast W,  Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery. J Neurosurg. 2022;138(5):1263\u20131272."},{"key":"b14","series-title":"Eur J Pharm Biopharm","first-page":"226","article-title":"Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use","volume":"104","author":"Ter Weele EJ","year":"2016","unstructured":"Ter Weele EJ, Terwisscha van Scheltinga AG, Linssen MD, Nagengast WB, Lindner I, Jorritsma-Smit A,  Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. Eur J Pharm Biopharm. 2016;104:226\u2013234."},{"issue":"1","key":"b15","series-title":"J Nucl Med","first-page":"82","article-title":"Intraoperative molecular fluorescence imaging of pancreatic cancer by targeting vascular endothelial growth factor: a multicenter feasibility dose-escalation study","volume":"64","author":"Sibinga Mulder BG","year":"2023","unstructured":"Sibinga Mulder BG, Koller M, Duiker EW, Farina Sarasqueta A, Burggraaf J, de Meijer VE,  Intraoperative molecular fluorescence imaging of pancreatic cancer by targeting vascular endothelial growth factor: a multicenter feasibility dose-escalation study. J Nucl Med. 2023;64(1):82\u201389."},{"issue":"2","key":"b16","series-title":"J Biomed Opt","first-page":"24001","article-title":"Toward optical guidance during endoscopic ultrasound-guided fine needle aspirations of pancreatic masses using single fiber reflectance spectroscopy: a feasibility study","volume":"22","author":"Stegehuis PL","year":"2017","unstructured":"Stegehuis PL, Boogerd LS, Inderson A,  Toward optical guidance during endoscopic ultrasound-guided fine needle aspirations of pancreatic masses using single fiber reflectance spectroscopy: a feasibility study. J Biomed Opt. 2017;22(2):24001."},{"issue":"1","key":"b17","series-title":"J Biomed Opt","first-page":"017004","article-title":"Integration of single-fiber reflectance spectroscopy into ultrasound-guided endoscopic lung cancer staging of mediastinal lymph nodes","volume":"15","author":"Kanick SC","year":"2010","unstructured":"Kanick SC, van der Leest C, Aerts JG,  Integration of single-fiber reflectance spectroscopy into ultrasound-guided endoscopic lung cancer staging of mediastinal lymph nodes. J Biomed Opt. 2010;15(1):017004."},{"issue":"19","key":"b18","series-title":"Theranostics","first-page":"5336","article-title":"Recommendations for reporting on emerging optical imaging agents to promote clinical approval","volume":"8","author":"Tummers WS","year":"2018","unstructured":"Tummers WS, Warram JM, van den Berg NS,  Recommendations for reporting on emerging optical imaging agents to promote clinical approval. Theranostics. 2018;8(19):5336\u20135347."},{"issue":"6","key":"b19","series-title":"J Neurosurg Sci","first-page":"661","article-title":"5-ALA fluorescence on tumors different from malignant gliomas. Review of the literature and our experience","volume":"63","author":"Boschi A","year":"2019","unstructured":"Boschi A, Della Puppa A. 5-ALA fluorescence on tumors different from malignant gliomas. Review of the literature and our experience. J Neurosurg Sci. 2019;63(6):661\u2013669."},{"issue":"4","key":"b20","series-title":"Neurosurg Rev","first-page":"799","article-title":"The application of fluorescence techniques in meningioma surgery\u2014a review","volume":"42","author":"Dijkstra BM","year":"2019","unstructured":"Dijkstra BM, Jeltema HJR, Kruijff S, Groen RJM. The application of fluorescence techniques in meningioma surgery\u2014a review. Neurosurg Rev. 2019;42(4):799\u2013809."},{"key":"b21","article-title":"Exploratory IND Studies: Guidance for Industry, Investigators, and Reviewers","year":"2006","unstructured":"Exploratory IND Studies: Guidance for Industry, Investigators, and Reviewers. Food & Drug Administration; 2006. Accessed April 24, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/exploratory-ind-studies"},{"key":"b22","series-title":"LICORbio","article-title":"Pearl\u00ae Trilogy specifications","unstructured":"Pearl\u00ae Trilogy specifications. LICORbio. Accessed April 24, 2024. https:\/\/www.licor.com\/bio\/pearl\/specifications"},{"key":"b23","article-title":"Operator\u2019s Manual for Labs Using Image StudioTM 21 CFR Part 11.","author":"Odyssey\u00ae CLx","year":"2019","unstructured":"Odyssey\u00ae CLx. Operator\u2019s Manual for Labs Using Image StudioTM 21 CFR Part 11.. LiCOR; 2019. Accessed April 24, 2024. http:\/\/www.licor.com\/documents\/yn0nwa8uqb3ro5jy8pr3u9v4ue47nzgn"},{"key":"b24","article-title":"INFRARED 800 Video Angiography: A Practical Guide for the Surgeon","author":"Raabe A","year":"2010","unstructured":"Raabe A. INFRARED 800 Video Angiography: A Practical Guide for the Surgeon. Bern University Hospital; 2010. Accessed April 24, 2024. https:\/\/pdf.medicalexpo.com\/pdf\/zeiss-medical-technology\/infrared-800\/67959-92761.html"},{"issue":"1","key":"b25","series-title":"Bioeng Transl Med","first-page":"e10182","article-title":"Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery","volume":"6","author":"He K","year":"2020","unstructured":"He K, Chi C, Li D,  Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery. Bioeng Transl Med. 2020;6(1):e10182."},{"issue":"9","key":"b26","series-title":"Theranostics","first-page":"2508","article-title":"First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN","volume":"8","author":"Li D","year":"2018","unstructured":"Li D, Zhang J, Chi C,  First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN. Theranostics. 2018;8(9):2508\u20132520."},{"issue":"1","key":"b27","series-title":"Mol Imaging Biol","first-page":"109","article-title":"Safety and stability of antibody-dye conjugate in optical molecular imaging","volume":"23","author":"Pei J","year":"2021","unstructured":"Pei J, Juniper G, van den Berg NS,  Safety and stability of antibody-dye conjugate in optical molecular imaging. Mol Imaging Biol. 2021;23(1):109\u2013116."},{"issue":"1","key":"b28","series-title":"J Neurooncol","first-page":"135","article-title":"First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800","volume":"139","author":"Miller SE","year":"2018","unstructured":"Miller SE, Tummers WS, Teraphongphom N,  First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. J Neurooncol. 2018;139(1):135\u2013143."},{"issue":"12","key":"b29","series-title":"Acta Neurochir (Wien)","first-page":"2263","article-title":"Immunohistochemical profile of the dural tail in intracranial meningiomas","volume":"156","author":"Wen M","year":"2014","unstructured":"Wen M, Jung S, Moon KS,  Immunohistochemical profile of the dural tail in intracranial meningiomas. Acta Neurochir (Wien). 2014;156(12):2263\u20132273."},{"issue":"5","key":"b30","series-title":"Oncol Lett","first-page":"1513","article-title":"Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas","volume":"5","author":"Wang W","year":"2013","unstructured":"Wang W, Da R, Wang M,  Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas. Oncol Lett. 2013;5(5):1513\u20131518."},{"issue":"4","key":"b31","series-title":"Ann Clin Lab Sci","first-page":"344","article-title":"Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas","volume":"38","author":"Ding YS","year":"2008","unstructured":"Ding YS, Wang HD, Tang K, Hu ZG, Jin W, Yan W. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci. 2008;38(4):344\u2013351."},{"issue":"4","key":"b32","series-title":"Pharmacol Rev","first-page":"549","article-title":"Vascular endothelial growth factor and angiogenesis","volume":"56","author":"Hoeben A","year":"2004","unstructured":"Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549\u2013580."},{"key":"b33","series-title":"Front Biosci","first-page":"D141","article-title":"Signal relays in the VEGF system","volume":"4","author":"Ortega N","year":"1999","unstructured":"Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci. 1999;4:D141\u2013D152."},{"key":"b34","series-title":"Curr Protoc Neurosci","first-page":"2.28.1","article-title":"Suppression of red blood cell autofluorescence for immunocytochemistry on fixed embryonic mouse tissue","volume":"81","author":"Whittington NC","year":"2017","unstructured":"Whittington NC, Wray S. Suppression of red blood cell autofluorescence for immunocytochemistry on fixed embryonic mouse tissue. Curr Protoc Neurosci. 2017;81:2.28.1\u20132.28.12."}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/141\/6\/article-p1655.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/141\/6\/article-p1655.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/141\/6\/article-p1655.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:45:29Z","timestamp":1734018329000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/141\/6\/article-p1655.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":34,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2024.4.jns232766","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}